On June 17, 2025 Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, reported it will present data on two novel nanomedicine radiotracers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21 – 24, 2025 in New Orleans, LA (Press release, Ashvattha Therapeutics, JUN 17, 2025, View Source [SID1234653943]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data will demonstrate the ability to tune Ashvattha’s hydroxyl dendrimer platform to achieve selective uptake in neuroinflammation in humans and in tumor-associated macrophages in cancer animal models.
The company will present findings on two novel nanomedicine radiotracers: flurimedrimer, which selectively targets activated microglia in the human brain to support its neurology pipeline, and a second radiotracer designed to selectively target tumor-associated macrophages, potentially advancing precision imaging in oncology.
SNMMI:
Poster Title: Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain
Presentation Date/Time: Sunday, June 22, 2025; 6:30-7:00pm CDT
Session Type: Molecular Targeting Probes POPs
Presenter: Farshad Moradi, MD, Stanford University
Poster Title: A Novel Nanomedicine Radiotracer, Selectively Targeting Tumor Associated Macrophages
Presentation Date/Time: Monday, June 23, 2025; 10:30 AM-11:15am CDT
Session Type: Poster Session
Presenter: Jeff Cleland, PhD, CEO, Ashvattha Therapeutics